
PHAR
Pharming Group N.V. develops and commercializes biopharmaceutical products, including the marketed drug Joenja (leniolisib) and the product Ruconest. The company operates across multiple therapeutic areas and holds various trademarks and intellectual property related to its pipeline and approved medicines. Based on the filing structure and product portfolio referenced, Pharming appears to be in both commercial and clinical development stages.